ArticleNature communications2019
Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- A Meta-Analysis ofG3 (Bethesda, Md.) · 2020Pooled it
- Efficacy of a eugenol-based nanoemulsion formulation incorporating a mosquitocidal Lysinibacillus sp. strain VCRC B654 against Culex quinquefasciatus under laboratory and simulated field conditions.Archives of microbiology · 2026Article
- Trace Mn Doping Optimized the Electronic Structure and Improved the Rate Performance of NaSmall (Weinheim an der Bergstrasse, Germany) · 2026Article
- Frequency and Distribution of Lymphatic Filariasis in Somalia: A Single-Center Experience.Journal of tropical medicine · 2026Article
- Autophagy is essential for anti-Frontiers in microbiology · 2026Article
- An open-source screening platform accelerates discovery of drug combinations.Nature communications · 2025Article
- Improved metagenome assemblies through selective enrichment of bacterial genomic DNA from eukaryotic host genomic DNA using ATAC-seq.Frontiers in microbiology · 2024Article
- Dual RNA-seq in filarial nematodes andFrontiers in microbiology · 2024Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- The cellular lives of Wolbachia.Nature reviews. Microbiology · 2023Review
- RECOVER identifies synergistic drug combinations in vitro through sequential model optimization.Cell reports methods · 2023Article
- The Proteome and Lipidome of Extracellular Vesicles fromInternational journal of molecular sciences · 2023Article
- Multiple lineages of nematode-Wolbachia symbiosis in supergroup F and convergent loss of bacterioferritin in filarial Wolbachia.Genome biology and evolution · 2023Article
- Multivariate chemogenomic screening prioritizes new macrofilaricidal leads.Communications biology · 2023Article
- Dirofilariasis mouse models for heartworm preclinical research.Frontiers in microbiology · 2023Article
- Current perspective of new anti-Wolbachial and direct-acting macrofilaricidal drugs as treatment strategies for human filariasis.GMS infectious diseases · 2022Review
- Thermal proteome profiling revealsFrontiers in pharmacology · 2022Article
- Current advances ofFrontiers in microbiology · 2022Review
- Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model.Parasitology research · 2021Review
- Development of Pyrazolopyrimidine Anti-ACS medicinal chemistry letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 3 countries.
Funding
Abstract
Nematodes causing lymphatic filariasis and onchocerciasis rely on their bacterial endosymbiont, Wolbachia, for survival and fecundity, making Wolbachia a promising therapeutic target. Here we perform a high-throughput screen of AstraZeneca's 1.3 million in-house compound library and identify 5 novel chemotypes with faster in vitro kill rates (<2 days) than existing anti-Wolbachia drugs that cure onchocerciasis and lymphatic filariasis. This industrial scale anthelmintic neglected tropical disease (NTD) screening campaign is the result of a partnership between the Anti-Wolbachia consortium (A∙WOL) and AstraZeneca. The campaign was informed throughout by rational prioritisation and triage of compounds using cheminformatics to balance chemical diversity and drug like properties reducing the chance of attrition from the outset. Ongoing development of these multiple chemotypes, all with superior time-kill kinetics than registered antibiotics with anti-Wolbachia activity, has the potential to improve upon the current therapeutic options and deliver improved, safer and more selective macrofilaricidal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.